Sagimet Biosciences Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SGMT Nasdaq 2830 www.sagimet.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sagimet Biosciences Inc.

Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet - Oct 23rd, 2026 6:55 am
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne - Oct 22nd, 2026 6:10 pm
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne - Oct 22nd, 2026 5:00 am
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - Oct 15th, 2026 6:35 am
Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial - Oct 9th, 2026 6:18 am
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference - Oct 9th, 2026 5:00 am
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch - Oct 3rd, 2026 7:02 pm
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - Oct 1st, 2026 2:31 pm
Sector Update: Healthcare Stocks Softer Wednesday Afternoon - Sep 30th, 2026 11:40 am
Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data - Sep 30th, 2026 7:52 am
Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market - Sep 30th, 2026 6:17 am
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell - Sep 30th, 2026 4:59 am
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - Sep 30th, 2026 4:19 am
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026 - Sep 30th, 2026 4:00 am
Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight - Sep 28th, 2026 11:00 am
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026 - Sep 28th, 2026 5:00 am
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts - Sep 27th, 2026 7:25 pm
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences - Sep 2nd, 2026 5:00 am
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026 - Aug 25th, 2026 5:00 am
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 17th, 2026 2:28 pm